Risk of stroke with typical and atypical anti-psychotics: A retrospective cohort study including unexposed subjects

Journal of Psychopharmacology

Volumn 22, Issue 1, 2008, Pages 39-46

  Sacchetti, Emilio ^a,b   Trifirò, Gianluca ^c   Caputi, Achille ^c   Turrina, Cesare ^a   Spina, Edoardo ^d   Cricelli, Claudio ^e   Brignoli, Ovidio ^e   Sessa, Emiliano ^e   Mazzaglia, Giampiero ^e  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e Italian College of General Practitioners   (Italy)

Author keywords

Atypical anti psychotics; Elderly; Incidence; Primary care; Stroke; Typical anti psychotics

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DEMOGRAPHY; FEMALE; GENERAL PRACTITIONER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSYCHOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STROKE; TIME SERIES ANALYSIS;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK; STROKE;

EID: 37749013455     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107080792     Document Type: Article

References (65)

1. Allebech P., Wistedt B. (1986) Mortality in schizophrenia: a ten year follow-up based on the Stokholm County inpatients register. Arch Gen Psychiatry 43: 650 - 653
2. Angst F., Stassen A.H., Clayton P.J., Angst J. (2002) Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disorders 68: 167 - 181
3. Brodaty H., Ames D., Snowdon J., Woodward M., Kirwan J., Clarnette R., Lee E., Lyons B., Grossman F. (2003) A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 64: 134-1-43
4. Brook O.H. (1985) Mortality in the long-stay population of Duch mental hospitals. Acta Psychiatr Scand 71: 626 - 635
5. Carson S., McDonagh M.S., Peterson K. (2006) A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc 54: 354 - 361
6. Chamorro A. (2004) Role of inflammation in stroke and atherothrombosis. Cardiovasc Dis 17: Suppl 3: 1 - 5
7. Committee on Safety of Medicines (2004) Atypical antipsychotic drugs and stroke. Available at http://www.mca.gov.uk/aboutagency/regframework/csm/csmhome. htm. Accessed Febr 18, 2005
8. Curkendall S.M., Mo J., Glasser D.B., Rose Stang M., Jones J.K. (2004) Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 65: 715 - 720
9. Davis B.R., Vogt T., Frost P.H., Burlando A., Cohen J., Wilson A., Brass L.M., Frishman W., Price T., Stamler J. (1998) Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke 29: 1333 - 1340
10. De Deyn P.P., Katz I.R., Brodaty H., Lyons B., Greenspan A., Burns A. (2005) Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg 107: 497 - 508
11. Di Carlo A., Inzitari D., Galati F., Baldereschi M., Giunta V., Grillo G., Furchi A., Manno V., Naso F., Vecchio A., Consoli D. (2003) A prospective community-based study of stroke in Souther Italy: the Vibo Valentia incidence of stroke stduy (VISS). Methodoloy, incidence and case fatality at 28 days, 3 and 12 months. Cerebrovasc Dis 16: 410 - 417
12. Dziedzic T., Gryz E.A., Turay W., Slowk A., Szczudlik A. (2004) Serum interleukin-6 soluble receptor in relation to interleukin-6 in stroke patients. J Mol Neurosci 24: 293 - 298
13. Elkind M.S., Sacco RL (1998) Stroke risk factors and stroke prevention. Semin Neurol 18: 429 - 440
14. Emea (2004) Public Statement on the Safety of Olanzapine (Zyprexa, Zyprexa Velotab). Available at www.emea.eu.int/pdfs/human/press/pus/085604en. pdf. Accessed Febr 2, 2006
15. FDA (2003) Safety alert - Risperdal. Available at www.fda.gov/medwatch/ SAFETY/2003/risperdal.htm Accessed Febr 27, 2006
16. FDA Public Health Advisory. (2005) Deaths with Antipsychotics in Elderly Patients with Behavioural Disturbances. Available at: http://www.fda.gov/cder/ drug/advisory/antipsychotics.htm. Accessed Apr 10, 2005
17. Filippi A., Bignamini AA, Sessa E., Samani F., Mazzaglia G. (2003 a) Secondary prevention of stroke in Italy: a cross-sectional survey in family practice. Stroke 34: 1010 - 1014
18. Filippi A., Sabatini A., Badioli L., Samani F., Mazzaglia G., Catapano A., Cricelli C. (2003 b) Effects of an automated electronic reminder in changing the anti-platelet drug-prescribing behaviour among Italian general practitioners in diabetic patients: an intervention trial. Diabetes Care 26: 1497 - 1500
19. Finkel S., Cozma C., Long S., Greenspan A., Mahmoud R., Baser O., Engelhart L. (2005) Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 17: 617 - 629.
20. Formiga F., Fort I., Perez-Casteion J.M., Ruiz D. (2005) Association between risperidone treatment and cerebrovascular adverse events in elderly patients with dementia. J Am Geriatr Soc 53: 1146 - 1148
21. Garver D.L., Tamas R.L., Holcomb J.A. (2003) Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology 28: 1515 - 1520
22. Gill S.S., Rochon P.A., Herrmann N., Lee P.E., Sykora K., Gunray N., Normand S., Gurwitz J.H., Marras C., Wodchis W.P., Mamdani M. (2005) Atypical antipsychotic drugs and risk of ischemic stroke: population based retrospective cohort study. BMJ 330: 445
23. Goldstein L.B. (2000) Novel risk factors for stroke: homocysteine, inflammation, and infection. Current Atherosclerosis Reports 2: 110 - 114
24. Health Canada (2005) Health Canada advises consumers about important safety information on atypical antipsychotic drugs and dementia. Available at www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2005/2005_63_e.html. Accessed April 12, 2006
25. Herrmann N., Mamdani M., Lanctot K.L. (2004) Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 161: 1113 - 1115
26. Hill M.D., Yiannakoulias N., Jeerakathil T., Tu J.V., Svenson L.W., Schopflocher D.P. (2004) The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 62: 2015 - 2020
27. Humphries S.E., Morgan L. (2004) Genetic risk factors for stroke and carotid atherosclerosis: insights into pathophysiology from candidate gene approaches. Lancet Neurol 3: 227 - 236
28. Johnston S.C., Gress D.R., Browner W.S., Sidney S. (2000) Short-term prognosis after emergency department diagnosis of TIA. JAMA 284: 2901 - 2906
29. Joukamaa M., Heliovaara M., Knekt P., Aromaa A., Raitasalo R., Lehtinen V. (2001) Mental disorders and cause-specific mortality. Br J Psychiatry 179: 498 - 502
30. Kolominsky-Rabas P.L., Sarti C., Heuschmann P.U., Graf C., Siemonsen S., Neundoerfer B., Katalinic A., Lang E., Gassman K.G., von Stokert T.N. (1998) A prospective community-based study of stroke in Germany - the Erlangen Stroke Project (ESPRro). incidence and case fatality at 1, 3 and 12 months. Stroke 29: 2501 - 2506
31. Lawlor B.A. (2004) Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. J Clin Psychiatry 65 (11 Ssuppl 11). 5 - 10
32. Lawrenson R., Williams T., Farmer R. (1999) Clinical information for research: the use of general practice databases. J Pub Health Med 21: 299 - 304
33. Layton D., Harris S., Wilton L.W., Shakir S A W (2005) Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attaks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol 19: 473 - 482
34. Leone M.A., Capponi A., Varrasi C., Tarletti R., Monaco F. (2004) Accuracy of the ICD-9 codes for identifying TIA and stroke in an Italian automated database. Neurol Sci 25: 281 - 288
35. Leucht S., Pitschel-Waltz G., Engel R.R., Kissling W. (2002) Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159: 180 - 190
36. Lindsberg P.J., Grau A.J. (2003) Inflammation and infections as risk factors for ischemic stroke. Stroke 34: 2518 - 2532
37. Liperoti R., Gambiassi G., Lapane K., Chiang C., Pedone C., Mor V., Bernabei R. (2005) Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 66: 1090 - 1096
38. Mayo N.E., Chockalingam A., Reeder B.A., Phillips S. (1994) Surveillance for stroke in Canada. Health Rep 6: 62 - 72
39. McCreadie R. on behalf of the Scottish Schizophrenia Lifestyle Group (2003) Diet, smoking and cardiovascular risk in people with schizophrenia. Descriptive study. Br J Psychiatry 183: 534 - 539
40. Mota Neto J I S, Lima M.S., Soares B G O (2007) Amisulpride for schizophrenia (Review). The Cochrane Library, Issue 1.
41. Mowat D., Fowlie D., MacEwan T. (2004) CSM warning on atypical psychotics and stroke may be detrimental for dementia. BMJ 328: 1262
42. Nelson J.C. (2005) Increased risk of cerebrovascular adverse events and death in elderly demented patients treated with atypical antipsychotics: what's a clinician to do? J Clin Psychiatry 66: 1071
43. O'Brien S.M., Scott L.W., Dinan T.G. (2004) Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 19: 397 - 403
44. Osby U., Brandt L., Correia N., Ekbon A., Sparen P. (2001) Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 58: 844 - 850
45. Osby U., Correia N., Brandt L., Ekbon A., Sparen P. (2000) Mortality and causes of death in schizophrenia in Stokholm County, Sweden. Schizophrenia Research 45: 21 - 28
46. Percudani M., Barbui C., Fortino I., Tansella M., Petrovich L. (2005) Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol 25: 468 - 470
47. Raju J., Sikdar S., Krishna T. (2005) What happened to patients with behavioural and psychological symptoms of dementia (BPSD) after the Committee on Safety in Medicines (CSM) guidelines ? Int J Geriatr Psychiatry 20: 898 - 899
48. Rothwell P.M., Warlow C.P. (2005) Timing of TIAs preceding stroke: time window for prevention is very short. Neurology 64: 817 - 820.
49. Sacchetti E., Turrina C., Parrinello G., Brignoli O., Stefanini G., Mazzaglia M. (2005) Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. International Clinical Psychopharmacology 20: 33 - 37
50. Sacco R.L., Benjamin E.J., Broderick J.P., Dyken M., Easton J.D., Feinberg W.M., Goldstein L.B., Gorelik P.B., Howard G., Kittner S.J., Manolio T.A., Whisnant J.P., Wolf P.A. (1997) American hearth association prevention conference IV: risk factors. Stroke 28: 1507 - 1517
51. Schwalb H., Schwalb M. (1987) Mortalitat hospitalisierter psychiatrischer Patienten: Ergebnisse einer 10-Jahres-Studie. Fortschr Neurol Psychiatr 55: 83 - 97
52. Shah A., Suh G.H. (2005) A case for judicious use of risperidone and olanzapine in behavioral and psychological symptoms of dementia (BPSD). Favour Int Psychogeriatr 17: 12 - 22
53. Shah B.R., Laupacis A., Hux J.E., Austin P.C. (2005) Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 58: 550
54. Smith D.A., Beier M.T. (2004) Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc 5: 129 - 132
55. Soares B G O, Fenton M., Chue P. (2007) Sulpiride for schizophrenia (Review). The Cochrane Library, Issue 1.
56. Straus S.M., Bleumink G.S., Dieleman J.P., van der Lei J., Jong G.W., Kingma J.H., Sturkenboom M.C., Stricker B.H. (2004) Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 164: 1293 - 1297
57. Street J.S., Clark W.S., Gannon K.S., Cumming J.L., Bymaster F.P., Tamura R.N., Mitan S.J., Kadam D.L., Sanger T.M., Feldman P.D., Tollefson G.D., Breier A. (2000) Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer Disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 57: 968 - 976
58. Sturmer T., Joshi M., Glynn R.J., Avorn J., Rothman K J, Schneeweiss (2006) A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 59: 437 - 447
59. Syme P.D., Byrne A.W., Chen R., Devenny R., Forbes J.F. (2005) Community-based stroke incidence in a Scottish population: the Scottish Borders Stroke Study. Stroke 36: 1837 - 1843
60. Trifiro G., Spina E., Brignoli O., Sessa E., Caputi A.P., Mazzaglia G. (2005) Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur J Clin Pharmacol 61: 47 - 53
61. Von Korff M., Wagner E.H., Saunders K. (1992) A Chronic Disease Score from automated pharmacy data. J Clin Epidemiol 45: 197 - 203
62. Wada-Isoe K., Wakutani J., Urakami K. (2004) Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients Acta Neurol Scand 110: 124 - 127
63. Wang P.S., Schneeweiss S., Avorn J., Fischer M.A., Mogun H., Solomon D.H., Brookhart M.A. (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New Eng J Medicine 353: 2335 - 2341
64. Zhang X.J., Zhou D.F., Shang P.J. (2002) Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia association with psychopatology. Schizof Res 57: 247 - 258
65. Zheng D., Macera C.A., Croft J.B., Giles W.H., Davis D., Scott W.K. (1997) Major depression and all-cause mortality among white adults in the United States. Am J Epidemiology 7: 213 - 218